EDIT Message Board Post 9190966 | Editas Medicine Inc.
home / stock / edit / edit message board
sarahslabo
(investorshub)
Posted on: May/02/2022 21:43:49
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168726613
1106: $EDIT-202, a Multiplexed CRISPR-Cas12a Gene-Edited iPSC-Derived NK
News, Short Squeeze, Breakout and More Instantly...
-
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal ...
-
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post- renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative con...